Pharmafile Logo
Pharmafocus logo
Advanced Search

plozasiran

Showing 1 posts of 1 posts found.

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026
Research and Development The European Medicines Agency (EMA), plozasiran

The European Medicines Agency (EMA) has recommended granting a marketing authorisation for Redemplo (plozasiran) to treat adults with familial chylomicronaemia …

News
The Gateway to Local Adoption Series

Latest content

Japanese pharma outsources earlier as peptide development challenges grow

April 29, 2026

Study suggests phospholipid therapy may impact fatty liver disease outcomes

April 29, 2026

FDA signals support for development of psychedelic therapies in mental healthmental health

April 28, 2026

New web series explores path from ophthalmic research to patient access

April 28, 2026

EMA backs plozasiran for rare lipid disorder with high pancreatitis risk

April 27, 2026